Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $30 to $35.
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $30 to $35.